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BACKGROUND: There are no universally accepted guidelines for the follow-up of individuals with cutaneous melanoma. Furthermore, to
date, there have been no randomised controlled trials of different models of melanoma follow-up care. This randomised controlled
trial was conducted to evaluate the effects of GP-led melanoma follow-up on patient satisfaction, follow-up guideline compliance,
anxiety and depression, as well as health status.
METHODS: A randomised controlled trial of GP-led follow-up of cutaneous melanoma was conducted over a period of 1 year with
assessment by self-completed questionnaires and review of general practice-held medical records at baseline and 12 months later. It
took place in 35 general practices in North-east Scotland. Subjects were 142 individuals (51.4% women 48.6% men; mean (s.d.) age
59.2 (15.2) years previously treated for cutaneous melanoma and free of recurrent disease. The intervention consisted of protocol-
driven melanoma reviews in primary care, conducted by trained GPs and supported by centralised recall, rapid access pathway to
secondary care and a patient information booklet. The main outcome measure was patient satisfaction measured by questionnaire.
Secondary outcomes were adherence to guidelines, health status measured by Short Form-36 and the Hospital Anxiety and
Depression Scale.
RESULTS: There were significant improvements in 5 out of 15 aspects of patient satisfaction during the study year in those receiving
GP-led melanoma follow-up (all Pp0.01). The intervention group was significantly more satisfied with 7 out of 15 aspects of care at
follow-up after adjustment for potential confounders. There was significantly greater adherence to guidelines in the intervention
group during the study year. There was no significant difference in health status or anxiety and depression between intervention and
control groups at either baseline or outcome.
CONCLUSIONS: GP-led follow-up is feasible, engenders greater satisfaction in those patients who receive it, permits closer adherence
to guidelines and does not result in adverse effects on health status or anxiety and depression when compared with traditional
hospital-based follow-up for melanoma.
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Patients treated for cutaneous melanoma are at a high risk of
recurrence and require careful follow-up (McCarthy et al, 1988;
Martini et al, 1994; Roberts et al, 2002; SIGN, 2003). Several
guidelines that give recommendations about the timing and
schedule of formal follow-up exist, based on current limited
evidence and expert opinion (Poo-Hwu et al, 1999; Roberts et al,
2002; SIGN, 2003). Despite this, there are no universally accepted
guidelines for follow-up, and none is specific about where it should
take place, or which health-care professional should deliver it
(Poo-Hwu et al, 1999; Roberts et al, 2002; SIGN, 2003). Further-
more, there have been no randomised trials of different follow-up
methods, for example, comparing follow-up by different
professionals or in different locations (Martinez and Otley, 2001;
SIGN, 2003; Francken et al, 2005).
There are several reasons to believe that a GP-led follow-up
programme for melanoma could be feasible and attractive, but it
could also have several potential problems. Individual practices are
likely to have small numbers of patients requiring melanoma
follow-up, which has the advantage that the programme may be
incorporated into the primary care workload with minimal
disruption and few resource issues, but the disadvantage that
skills might be practised infrequently. However, as melanoma
follow-up is based on elements of clinical examination practised
routinely in primary care, patient self-examination and patient
education, GPs might be able to provide a service that is equivalent
in clinical outcome to specialist follow-up. Support for this
view comes from three randomised controlled trials, two in
women with breast cancer and one in individuals with colorectal
cancer, wherein a follow-up programme based on GP examination,
patient self-examination and education, demonstrated equivalent
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soutcomes to those achieved in secondary care (Grunfeld et al,
1999, 2006; Wattchow et al, 2006). Although hospitals may offer
more focused specialist consultations, primary care may offer
more holistic consultations; this notion has been suggested by
earlier studies and was confirmed in a parallel qualitative study to
this randomised trial (Grunfeld et al, 1999; Murchie et al, 2010).
A key aim of follow-up is to detect recurrences and new primaries
early, but most of these events have been found to occur during
the intervals between follow-up appointments; therefore, patient
education may be more important than review examinations
(Meyers et al, 2009). It is not clear whether specialists or primary
care are best at enabling patients to understand self-examination,
but primary care may have more time, more opportunities for
reinforcement and greater continuity. On the other hand,
individuals with melanoma may value regular review by specialists
and be less reassured by GP review.
We developed a GP-led follow-up programme for cutaneous
melanoma according to the principles of the MRC framework for
the design and evaluation of complex health-care interventions to
improve health (Murchie et al, 2007). In a 1-year exploratory
randomised controlled trial in North-east Scotland, we evaluated
its effect on patient satisfaction, follow-up guideline compliance,
anxiety and depression, as well as health status.
METHODS
Setting and participants
This study was conducted in North-east Scotland (population
B500000) between April 2005 and April 2006. A total of 35 general
practices from across the region agreed to participate. Each
participating practice was presented with a list of their patients
currently attending the joint hospital melanoma clinic at the
Aberdeen Royal Infirmary (ARI) and asked to supplement this
with a search of their own practice computer records for patients
with melanoma. They were then asked to ensure that all identified
patients met the inclusion criteria (Box 1).
Sample size calculation
This was an open cluster randomised trial designed to avoid the
risk of contamination and minimise bias. As most participants
would normally be attending the joint melanoma clinic at the ARI,
the size of the intra-cluster correlation coefficient (ICC) between
participants at different general practices in baseline satisfaction
with existing hospital-based follow-up was unlikely to be large;
therefore, a conservative ICC of 0.01 was estimated. With 40
practices and 150 participants, and assuming baseline levels of
satisfaction of 60% for service delivery, 65% for the consultation
and 40% for continuity of care (Grunfeld et al, 1999), the resultant
trial would have 80% power to detect differences of at least 20% in
each of the three domains of patient satisfaction, at the two-sided
5% significance level.
Randomisation
Randomisation was conducted by the principal investigator
PM. Practices were stratified according to the number of eligible
patients likely to be available in each practice on the basis of a list
provided by the joint melanoma clinic at the ARI. Three strata
were formed: practices with 45 eligible patients, 4–5 eligible
patients and p3 eligible participants. Strata were checked to
ensure an equal balance of rural (X15 miles from the Aberdeen
City centre) and urban (o15 miles from the Aberdeen City centre)
practices. Practices were then randomised within each stratum to
intervention or control using the randomisation function of the
computer software package SPSS version 15.0 (SPSS Inc., Chicago,
IL, USA). Participants were not blinded as to group allocation.
The intervention
Complete details of the intervention and its design have been
published previously (Murchie et al, 2007). Briefly, a lead GP from
each of the intervention practices attended a 4-h training session
and received a comprehensive information manual detailing how
to deliver the study protocol for a 12-month period. This session
focused on the presentation of new and recurrent melanomas and
how best to examine to identify these. Participating GPs received
travel and locum expenses to attend training. In three cases (in
which the lead GP was unable to attend the training session), the
principal investigator (PM) visited the practices and delivered a
modified training session to the GP. All patients in the intervention
group received a detailed information booklet about melanoma,
which included information on conducting self-examination.
A computerised recall register of the intervention group patients
was constructed in Microsoft Excel (Microsoft, Redmond, WA,
USA) and maintained by the principal investigator. The interven-
tion group patients were invited to attend scheduled protocol-
based melanoma follow-up appointments with the lead GP at their
practice, at 3 or 6-monthly intervals depending on the thickness of
melanoma and time since diagnosis. This schedule of visits is
identical to that followed by the specialists running the Joint
Melanoma Clinic at the ARI, and is informed by the frequency of
visits recommended in national guidelines (Roberts et al, 2002;
SIGN, 2003). At each appointment, the GP took a focused history,
and conducted a structured examination of the melanoma primary
site and regional lymph nodes. Imaging, blood tests or dermoscopy
were not performed as these are not recommended in the current
UK Guidelines (Roberts et al, 2002; SIGN, 2003). At the first GP
follow-up appointment only, the GP conducted a complete skin
survey. Moreover, at the first visit, the GP instructed the patient on
how to conduct a self-examination, an issue revisited at each
subsequent follow-up visit. Whenever concern arose regarding
possible recurrence during or between scheduled follow-up
appointments, patients could be referred through a rapid referral
pathway to the plastic surgery outpatient clinic at the ARI.
Participating practices received d30 per follow-up visit towards
practice participation costs. The GPs at control practices received
no training in melanoma follow-up and had no scheduled
consultations with their patients as part of the study. Patients at
practices randomised to the control group continued to attend the
hospital-based joint melanoma clinic for their melanoma follow-
up, at 3 or 6-monthly intervals depending on the thickness of
melanoma and time since diagnosis. The joint melanoma clinic is
run by specialists from plastic surgery, oncology and dermatology,
Box 1 Agreed inclusion and exclusion criteria for the randomised study
Eligible if gave informed consent and diagnosed with and
successfully treated for primary cutaneous malignant melanoma
within the last 10 years.
Include the following:
Those with cutaneous malignant melanoma p4mm and diagnosed more
than 6 months but o10 years previously.
Those with cutaneous malignant melanoma 44mm diagnosed more than
3 years but o10 years previously.
Exclude if:
Previous cutaneous malignant melanoma but timing of diagnosis and/or
Breslow depth with inclusion parameters.
Active metastatic disease.
Active recurrence (i.e., o1 year ago).
Dementia or significant psychiatric illness making informed consent impossible.
Unable to comply with trial protocol, or terminally ill, housebound or own GP
views patient participation as unsuitable.
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sand attending patients have primary tumour site, nodal basins,
abdomen and other abnormal moles examined by one of these
specialists or a trainee.
Data collection
Data were collected at baseline and after 12 months from the
following two sources: (i) a self-completed postal patient
questionnaire (comprising questions on demographic and socio-
economic status, a questionnaire to ascertain patient satisfaction
(Grunfeld et al, 1999), the Short Form-36 (SF-36) questionnaire
(Ware, 1993) and the Hospital Anxiety and Depression Scale
(HADS) (Zigmond and Snaith, 1983)) and (ii) patients’ general
practice-held medical records for information about the initial
melanoma diagnosis as well as treatment and use of primary and
secondary care services in the previous 12 months.
Outcome measures
Primary outcome The primary outcome of the trial was patient
satisfaction. Patients were asked to rate, on a four-point Likert scale,
their agreement with statements about 15 aspects of follow-up
covering service delivery, the consultation and continuity of care
(Table 2). Owing to small numbers, the answers were combined to
create a binary variable for analysis. For each item, ‘agree’ was
combined with ‘agree sometimes’ and ‘disagree’ was combined with
‘can’t say’. This was because the satisfaction instrument is attitudinal
and based on a Rasch model, in which combing adjacent categories
is permitted, provided they signify related levels of the variable being
measured. (Wright and Linacre, 1992). The satisfaction question-
naire had been developed for use in a randomised trial of GP-led
breast cancer follow-up (Grunfeld et al, 1999), and Cronbach’s
a-values of 0.70, 0.67 and 0.70 at baseline, 6 weeks and 3 months have
been reported. Answers to the 15 individual questions were then
combined into a total satisfaction summary score of between 15
(total satisfaction) and 60 (total dissatisfaction).
Secondary outcomes Adherence to local guidelines was deter-
mined in relation to the current locally recommended schedule
from the hospital joint melanoma clinic (Box 2). Guideline
adherence was a binary variable, with the care of patients
considered adherent if the general practice-held medical records
indicated that they had had, in the preceding 12 months, the
correct number of joint melanoma clinic or GP melanoma follow-
up visits as deemed appropriate for the Breslow thickness and time
since initial diagnosis. Health status was assessed using the SF-36
(Ware, 1993; Lyons et al, 1995) and the HADS (Zigmond and
Snaith, 1983; Bjelland et al, 2002).
Statistical analysis
The questionnaires were coded and all data entered manually
using Microsoft Office Access 2003 (Microsoft). The data were
analysed using SPSS for Windows version 15.0 and STATA 10
(StataCorp, College Station, TX, USA).
Satisfaction, adherence to guidelines and HADS status between
intervention and control groups at baseline and follow-up were
compared using the cluster-adjusted w
2 test based on the general-
ised estimating equations (GEEs) approach, on the assumption
that there was working exchangeable correlation among patients
within the same cluster (Donner and Klar, 1994). It is now
recognised that changes in SF-36 scores between two points in time
for six domains (namely physical functioning, social functioning,
mental health, energy and vitality, bodily pain and general health),
as well as for the physical and mental component summary scores
have a normal distribution (Fayers and Machin, 2000). For this
reason, the cluster-adjusted t-test was used to compare the mean
summary satisfaction score and SF-36 scores between intervention
and control groups at the two time points (Donner and Klar, 2000).
The cluster-adjusted McNemar’s w
2 test was used to compare
change in each aspect of satisfaction, adherence to guidelines and
HADS group between baseline and follow-up within the interven-
tion and control groups separately (Durkalski et al, 2003).
Unadjusted odds ratios (ORs) and their 95% confidence interval
(95% CI) were estimated through GEEs using robust (hetero-
skedasticity-corrected) s.e. to increase the efficiency of estimation
(Donner and Klar, 1994). The ORs were then adjusted for variables
selected a priori as potential confounders (gender, age, practice
size, distance of home from ARI, educational status, level of
satisfaction at baseline and practice). Owing to the number of
statistical tests performed, and the increased chance of a type 1
error, a P-value of p0.01 was used to denote statistical significance
throughout the univariate analyses.
RESULTS
Recruitment
Overall, 35 of the 83 practices approached (42.2%) agreed to
participate, and a total of 207 potentially eligible patients were
identified (Figure 1). Of these, 142 (68.6%) patients agreed to
participate in the study, resulting in 17 practices with 53 patients in
the intervention group and 18 practices with 89 patients in the
control group. The imbalance in numbers was a result of lower
recruitment than anticipated in several larger practices.
The intervention and control groups were comparable for age,
sex, socioeconomic factors and features of their melanoma, but
those in the intervention group tended to live further away from
the ARI (Table 1).
Patient satisfaction
At baseline, there was no significant difference between groups in
any of the 15 aspects of the patient satisfaction measured (Table 2).
At follow-up, more participants in the intervention group agreed
with different aspects of satisfaction than did those in the control
group. There were statistically significant differences between
groups on 6 of the 15 aspects assessed. Members of the
intervention group were significantly more likely than those in
the control group to believe that ‘it’s easy to get through by phone
if you need to’; that ‘if I feel I need to I can usually see a doctor on
the same day’; that ‘you are usually seen within 20 minutes of your
appointment time’; that ‘the doctor examines you thoroughly when
Box 2 Grampian guidelines for the follow-up of cutaneous melanoma
Melanoma follow-up schedule
Thickness Follow-up
In situ One month appointment at the joint melanoma clinic
for diagnosis and prognosis then discharge.
o1mm One month appointment at the joint melanoma clinic
for diagnosis and prognosis.
Then 3 monthly for 3 years.
1–4mm One month appointment at the joint melanoma clinic
for diagnosis and prognosis.
Then 3 monthly for 3 years.
Then 6 monthly for 5–10 years.
44mm One month appointment at the joint melanoma clinic
for diagnosis and prognosis.
Then monthly for 6 months.
Then 3 monthly for 3 years.
Then 6 monthly for 5–10 years.
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snecessary’; that ‘the doctor always prescribes medicine if you need
it’; and that ‘you see a doctor who know you well.’
At baseline, there was no significant difference between
groups in the cluster-adjusted mean summary satisfaction score
(P¼0.912). At follow-up, the cluster-adjusted mean score was
significantly lower in the intervention group 26.4 (95% CI: 24.9–
27.9) vs 33.5 (95% CI: 32.5–34.4), indicating significantly higher
satisfaction than in controls (Po0.001).
Within the intervention group, there was a statistically signi-
ficant change over time in the level of agreement in satisfaction
with 5 of 15 aspects of care (Table 3). In contrast, within the
control group, there were no significant changes over time. Change
(from baseline to follow-up) in the mean summary score was
found to be significantly lower ( 5.96, 95% CI:  8.09 to  3.89)
in the intervention group than in the control group (0.29, 95%
CI:  1.49 to 2.08) (P¼0.001), indicating higher overall satisfaction.
Of the 13 aspects of satisfaction wherein ORs could be
computed, there was statistically significant higher satisfaction in
the intervention group for 7 aspects after adjustment for clustering
and potential confounders (Table 4).
Adherence to guidelines
In the year before the study, 84.9% of the individuals in the
intervention group and 85.4% of the control group had been seen in
accordance with the local guidelines (P¼0.86). At follow-up, 98.1% of
the individuals in the intervention group were seen according to local
guidelines, compared with 80.9% of the control group (P¼0.020).
Health status and psychological well-being
There was no statistically significant difference between groups in
terms of distribution of SF-36 scores at either baseline or follow-up
(Table 5). There was no statistically significant difference in the
Table 1 Baseline characteristics of each group
Intervention Control
Demographics
Gender
Male n (%) 28 (52.8) 41 (46.1)
Female n (%) 25 (47.2) 48 (53.9)
Age at start of trial
Years – mean (s.d.) 58.7 (14.6) 59.5 (15.5)
Employment status
Full-time work n (%) 21 (42.0) 30 (38.0)
Part-time work n (%) 4 (8.0) 9 (11.4)
Retired n (%) 24 (48.0) 34 (43.0)
Unemployed n (%) 0 (0) 1 (1.3)
At home n (%) 1 (2.0) 2 (2.5)
Other n (%) 0 (0) 3 (3.8)
Educational level
None n (%) 11 (22) 14 (17.5)
O grades n (%) 8 (16.0) 15 (18.8)
Highers n (%) 1 (2.0) 3 (3.8)
Vocational or technical n (%) 13 (26.0) 13 (16.3)
Degree or professional n (%) 17 (34.0) 33 (41.3)
Other n (%) 0 (0) 2 (2.5)
Melanoma details
Site
Head or neck n (%) 13 (24.5) 15 (16.9)
Back n (%) 9 (17.0) 17 (19.1)
Chest or abdomen n (%) 8 (15.1) 7 (7.9)
Arm n (%) 5 (9.4) 11 (12.4)
Leg n (%) 15 (28.3) 28 (31.5)
Acral n (%)
a 2 (3.8) 11 (12.4)
Primary not identified n (%) 1 (1.9) 0 (0)
Breslow thickness
Median (IQR) 0.6 (0.25–1.5) 0.9 (0.4–1.7)
Breslow thickness categories (mm)
o1 n (%) 30 (56.6) 48 (53.9)
1–4 n (%) 20 (37.7) 33 (37.1)
44 n (%) 3 (5.7) 8 (9.0)
Time since diagnosis at the start of the trial (months)
Median (IQR) 49 (19–76) 63 (31–88.5)
Time since diagnosis categories (months)
1–36 n (%) 23 (43.4) 28 (31.5)
37–120 n (%) 23 (43.4) 55 (61.8)
121–316 n (%) 7 (13.2) 6 (6.7)
Home location
Distance from ARI
Miles—median (IQR) 27.6 (18.9–32.3) 10.1 (2.3–25.9)
Distance from GP practice
Miles—median (IQR) 1.6 (0.8–5.0) 1.5 (0.8–3.6)
Distance categories (miles)
0–19 n (%) 15 (28.3) 60 (67.4)
20–39 n (%) 31 (68.9) 14 (15.7)
440 n (%) 7 (31.8) 15 (16.9)
Travelling time to ARI
Minutes—median (IQR) 38.0 (28.5–46.0) 19.0 (7.0–33.0)
Travelling time categories (min)
0–30 n (%) 15 (28.3) 63 (70.8)
31–60 n (%) 32 (60.4) 14 (15.7)
60–90 n (%) 6 (11.3) 12 (13.5)
Practice
Practice size (list size at participants general practice)
Up to 7000 n (%) 4 (7.5) 14 (15.7)
7000–10000 n (%) 31 (58.5) 23 (25.8)
More than 10000 n (%) 18 (34.0) 52 (58.4)
Follow-up attendance
Total joint melanoma clinic attendances before trial
Median (IQR) 6 (2–11) 8 (2–12)
Joint melanoma clinic attendance categories
0 n (%) 11 (20.8) 18 (20.2)
1–6 n (%) 16 (30.2) 20 (22.5)
7–26 n (%) 26 (49.1) 51 (57.3)
Abbreviations: IQR¼interquartile range; ARI¼Aberdeen Royal Infirmary; GP¼
general practitioner.
aAcral melanomas are those affecting the extremities, namely nail
bed, palmar and plantar melanomas.
207 patients assessed as eligible
and invited to participate
38 did not respond
24 refused to take part
3 diagnosed more than
10 years previously
and discharged from
joint melanoma clinic
142 gave written
consent to be included
89 randomised to control
to continue with
traditional follow-up
86 completed
3 deaths
0 dropouts
53 randomised to
receive GP-led
melanoma follow-up
51 completed
1 death
1 dropout   
1 recurrence
1 new primary  
1 recurrence
1 new primary  
Figure 1 Consort diagram illustrating participant flow.
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sproportion of intervention and control group participants with a
HADS score, suggesting anxiety or depression (X8) either at base-
line or follow-up (Table 6). Similarly, there was no statistically signi-
ficant within-group difference between baseline and follow-up in the
proportion of patients exhibiting a likelihood of caseness for anxiety
or depression (HADS score X8) (Table 7) (Bjelland et al,2 0 0 2 ) .
Referrals and adverse events
A total of 146 GP follow-up appointments took place during the
study year. No problems were detected during 136 (93.2%) of these
appointments. In all, 10 (6.8%) scheduled follow-up appointments
resulted in urgent referrals through the rapid access pathway.
Nine adverse events occurred during the trial, of which four
were related to melanoma. There were two diagnoses of recurrent
melanoma, one in each group, with one patient dying before the
study was completed. Two new primaries, one in each group, were
detected during the trial year. Unrelated to melanoma, three
patients died (all belonging to the control group) and two, one in
either group, were diagnosed with another cancer.
DISCUSSION
Main findings
We found that GP-led melanoma follow-up improved patient satis-
faction and was more guideline compliant than hospital-based follow-
up. Health status and psychological well-being of those participants
receiving the new intervention seemed to be relatively unaffected.
Strengths and limitations
The GP-led follow-up programme was developed over a period of
12 months using the MRC framework for the development and
Table 2 Proportion of people indicating satisfaction with different aspects of care at baseline and follow-up, by group
Agree
n (%)
Do not agree
n (%)
Agree
n (%)
Do not agree
n (%)
Aspect of satisfaction Group Baseline Baseline P-value Follow-up Follow-up P-value
Service delivery
It is easy to get through by phone if you need to Intervention 33 (70.2) 14 (29.8) 48 (98.0) 1 (2.0)
Control 52 (73.2) 19 (26.8) 0.799 49 (71.0) 20 (29.0) o0.001
The reception staff are helpful Intervention 47 (97.9) 1 (2.1) 48 (98.0) 1 (2.0)
Control 71 (97.3) 2 (2.7) 0.955 62 (91.2) 6 (8.8) 0.112
If I feel I need to I can usually see a doctor on the same day Intervention 17 (36.2) 30 (63.8) 40 (81.6) 9 (18.4)
Control 22 (31.0) 49 (69.0) 0.512 26 (38.8) 41 (61.2) o0.001
You are usually seen within 20min of your appointment time Intervention 37 (75.5) 12 (24.5) 49 (100) 0 (0)
Control 56 (75.7) 18 (24.3) 0.991 54 (78.3) 15 (12.7) o0.001
The consultation
There is not enough time to discuss your problems with the
doctor
Intervention 20 (41.7) 28 (58.3) 9 (18.4) 40 (81.6)
Control 29 (40.8) 42 (59.2) 0.899 21 (30.9) 47 (69.1) 0.064
You get good advice about how to keep yourself healthy Intervention 32 (68.1) 15 (31.9) 46 (93.9) 3 (6.1)
Control 51 (70.8) 21 (29.2) 0.738 53 (77.9) 15 (22.1) 0.022
It is sometimes difficult to discuss your concerns with the doctor Intervention 22 (45.8) 26 (54.2) 8 (16.3) 41 (83.7)
Control 20 (28.2) 51 (71.8) 0.087 17 (25.4) 50 (74.6) 0.371
The doctor explains clearly what is wrong Intervention 40 (87.0) 6 (13.0) 46 (95.8) 2 (4.2)
Control 60 (84.5) 11 (15.5) 0.957 62 (91.2) 6 (8.8) 0.330
The doctor examines you thoroughly when necessary Intervention 44 (89.8) 5 (10.2) 49 (100) 0 (0)
Control 65 (90.3) 7 (9.7) 0.957 61 (91.0) 6 (9.0) o0.001
Sometimes you feel the doctor should listen more to what
you say
Intervention 19 (39.6) 29 (60.4) 9 (18.8) 39 (81.3)
Control 18 (25.7) 52 (74.3) 0.146 15 (22.7) 51 (77.3) 0.664
The doctor should tell you more about your problem
and treatment
Intervention 27 (57.4) 20 (38.5) 13 (27.1) 35 (72.9)
Control 38 (54.3) 32 (45.7) 0.649 20 (30.8) 45 (69.2) 0.338
The doctor encourages you to talk about your problem
and treatment
Intervention 31 (66.0) 16 (34.0) 45 (91.8) 4 (8.2)
Control 58 (81.7) 13 (18.3) 0.039 52 (78.8) 14 (21.2) 0.108
The doctor always prescribes medicine if you need it Intervention 15 (30) 35 (70) 38 (77.6) 11 (22.4)
Control 17 (24.6) 52 (75.3) 0.501 19 (28.8) 47 (71.2) o0.001
Continuity of care
You see a doctor who knows you well Intervention 19 (38.8) 30 (61.2) 45 (91.8) 4 (8.2)
Control 30 (41.1) 43 (58.9) 0.784 33 (48.5) 35 (51.5) o0.001
If you need to see a doctor, you have to wait too long
for the doctor you want
Intervention 11 (22.4) 38 (77.6) 14 (28.6) 35 (71.4)
Control 15 (21.7) 54 (78.3) 0.884 15 (22.4) 52 (77.6)
Baseline Intervention
Satisfaction summary score
a Intervention 32.6 (30.4–34.8) 26.4 (24.9–27.9)
Control 32.5 (30.7–34.2) 0.912 33.5 (32.5–34.4) o0.001
aValues are mean (95% confidence interval). The bolded P values indicate those associated with significance differences.
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sTable 3 Number of people indicating satisfaction with different aspects of care before and after the intervention
Intervention Control
Follow-up Follow-up
Aspect of satisfaction Baseline
Agree
n
Do not
agree nP -value
Agree
n
Do not
agree nP -value
Service delivery
It is easy to get through by phone if you need to Agree 30 1 38 6
Disagree 14 0 0.022 8 10 0.231
The reception staff are helpful Agree 44 1 58 3
Disagree 1 0 0.654 1 1 0.516
If I feel I need to I can usually see a doctor on the same day Agree 14 3 16 4
Disagree 22 6 0.003 9 31 0.230
You are usually seen within 20min of your appointment time Agree 36 0 45 4
Disagree 11 0 0.017 8 8 0.298
The consultation
There is not enough time to discuss your problems with the doctor Agree 5 13 13 11
Disagree 3 25 0.014 6 31 0.321
You get good advice about how to keep yourself healthy Agree 31 0 40 6
Disagree 12 2 0.005 11 6 0.640
It is sometimes difficult to discuss your concerns with the doctor Agree 4 16 8 6
Disagree 3 23 0.011 7 41 0.921
The doctor explains clearly what is wrong Agree 37 0 51 2
Disagree 5 1 0.056 7 2 0.046
The doctor examines you thoroughly when necessary Agree 43 0 54 2
Disagree 4 0 0.162 4 2 0.310
Sometimes you feel the doctor should listen more to what you say Agree 4 14 6 7
Disagree 4 23 0.019 7 40 0.922
The doctor should tell you more about your problem and treatment Agree 11 14 14 14
Disagree 1 18 0.008 2 29 0.012
The doctor encourages you to talk about your problem and treatment Agree 29 0 46 5
Disagree 13 3 0.014 3 7 0.313
The doctor always prescribes medicine if you need it Agree 13 2 11 4
Disagree 24 9 0.001 6 38 0.311
Continuity of care
You see a doctor who knows you well Agree 18 0 21 3
Disagree 25 4 o0.001 11 29 0.074
If you need to see a doctor, you have to wait too long for the doctor you want Agree 5 5 7 5
Disagree 8 29 0.510 7 41 0.723
Table 4 Chances of agreeing at follow-up with various statements of satisfaction with aspects of care of follow-up in the intervention group, compared
with the control group (expressed as odds ratio (95% confidence interval (CI)
Aspect of patient satisfaction Unadjusted odds ratio (95% CI) Adjusted odds ratio
a (95%CI)
Service delivery
It is easy to get through by phone if you need to 18.0 (2.5–128.6) 26.3 (4.8–143.2)
The reception staff are helpful 5.1 (0.7–38.5) 5.4 (1.0–28.5)
If I feel I need to I can usually see a doctor on the same day 6.7 (2.6–17.1) 7.6 (2.1–26.9)
You are usually seen within 20min of your appointment time NA NA
The consultation
There is not enough time to discuss your problems with the doctor 0.5 (0.2–1.0) 0.4 (0.2–0.8)
You get good advice about how to keep yourself healthy 4.3 (1.2–14.9) 8.1 (1.2–53.9)
It is sometimes difficult to discuss your concerns with the doctor 0.6 (0.2–2.0) 0.3 (0.1–1.1)
The doctor explains clearly what is wrong 2.3 (0.4–11.5) 25.8 (2.0–332.6)
The doctor examines you thoroughly when necessary NA NA
Sometimes you feel the doctor should listen more to what you say 0.9 (0.4–1.7) 1.3 (0.6–2.9)
The doctor should tell you more about your problem and treatment 0.8 (0.6–1.3) 0.7 (0.3–1.4)
The doctor encourages you to talk about your problem and treatment 2.9 (0.8–10.9) 88.7 (7.2–1087.1)
The doctor always prescribes medicine if you need it 8.7 (3.4–22.5) 23.8 (6.0–95.1)
Continuity of care
You see a doctor who knows you well 12.5 (4.6–33.8) 30.2 (8.5–107.8)
If you need to see a doctor, you have to wait too long for the doctor you want 1.4 (0.6–2.9) 0.8 (0.3–1.8)
Abbreviations: CI¼confidence interval; NA¼not applicable. These odds ratios could not be computed because of the small number of data and the consequent instability of
the model.
aAdjusted for gender, age, practice size, distance of home from the Aberdeen Royal Infirmary, educational status and level of agreement at baseline.
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sevaluation of complex interventions to improve health (Murchie
et al, 2007), resulting in a robust intervention that functioned with
few practical difficulties. A total of 42% of practices in the
Grampian region agreed to participate in the study. This is a
relatively high recruitment rate for an interventional trial in
primary care and increases the chances that the results are
applicable to the whole of this large geographical area (Foy et al,
2003). We randomised by practice to avoid contamination, but
lower than expected recruitment in some practices resulted in
eight clusters with fewer than three participants each after follow-
up. This complicated our analysis, but the use of the GEE approach
enabled us to account for the effect of clustering throughout all
analyses.
We were unable to investigate the effect of the intervention on
clinical end points, such as recurrence and mortality. Post hoc
power calculations indicate that, to obtain definitive data on
mortality and recurrence, a study of at least 2000 patients would be
required, and this is unlikely ever to be funded. Our study,
therefore, provides a firm basis if such a major undertaking were
ever to be contemplated. On the other hand, it seems likely that
research in this important clinical area will have to depend in
future on softer outcomes, and our data contribute considerably to
sparse current literature. Furthermore, although we detected no
significant difference in health status or anxiety and depression,
our trial had limited power to detect small or moderate-sized
changes.
The trial was not blinded. Patients were aware that they were in
the control group, not receiving the novel GP-led follow-up
programme. Our results would have been affected if patients in the
control group became, or remained, more dissatisfied than those
in the intervention group, because they knew that they remained
under hospital follow-up.
Our recruitment rate of 67% is high, but 38 of those patients
invited to participate did not respond and 28 declined to take
part. We have no information on the reasons for refusal or non-
response, but it may be that GP-led melanoma follow-up is
attractive and acceptable to many, but not all, patients.
Owing to limitations of funding, the study ran for only 1 year.
According to the protocol, 22 members of the intervention group
required a 3-monthly follow-up and 31 required a 6-monthly
follow-up. As a result, the median number of GP-led melanoma
follow-up appointments experienced by the intervention group
was two. This may have limited their ability to make comparisons
with their hospital follow-up. At the conclusion of the trial,
melanoma follow-up by GPs ended and patients were discharged
back to the melanoma clinic. Although the intervention seemed to
have been successful over the course of the year, it is not known
whether the benefits would have been sustained over a longer
period.
Comparison with other research
Several questionnaire and qualitative studies have explored the
views of patients about the possibility of receiving cancer follow-
up from their GPs (Adewuyi-Dalton et al, 1998; Howells et al, 1999;
Rozmovits et al, 2004; Dancey et al, 2005). Most suggest that a
significant proportion of patients would consider primary care-led
cancer follow-up to be acceptable, including 60% of 217
individuals attending follow-up after melanoma at a plastic
surgical outpatient clinic in an English hospital in 2003 (Dancey
et al, 2005). Three randomised trials, two for breast and one for
colorectal cancer, have examined follow-up based in primary care,
with the GP responsible for delivering the intervention (Grunfeld
et al, 1996, 1999, 2006; Wattchow et al, 2006). In each case, the GP-
led programme performed at least as well as traditional hospital-
based follow-up, although the outcome measures varied from trial
to trial. Several small surveys provide evidence about the
willingness of UK GPs to become involved in the follow-up of
patients with cancer, including melanoma (Grunfeld et al, 1995;
Papagrigoriadis and Heyman, 2001; Moses et al, 2004; Dancey et al,
2005).
Taken together, the evidence suggests that a sizeable proportion
of individuals with cancer are willing to consider alternatives to
Table 5 Median and interquartile range (IQR) SF-36 scores
Median IQR P-value
Physical functioning Baseline Intervention 95 90–100
Control 90 80–100 0.273
Outcome Intervention 95 85–100
Control 90 70.55–100 0.330
Social functioning Baseline Intervention 100 75–100
Control 100 75–100 0.344
Outcome Intervention 100 78.125–100
Control 100 75–100 0.560
Role physical Baseline Intervention 100 100–100
Control 100 75–100 0.381
Outcome Intervention 100 100–100
Control 100 50–100 0.149
Role emotional Baseline Intervention 100 100–100
Control 100 100–100 0.467
Outcome Intervention 100 100–100
Control 100 100–100 0.419
Mental health Baseline Intervention 84 68–92
Control 82 68–92 0.898
Outcome Intervention 84 72–92
Control 84 72–92 0.730
Energy and vitality Baseline Intervention 67.5 55–83.75
Control 70 52–96 0.793
Outcome Intervention 70 60–80
Control 70 46.25–83.75 0.698
Bodily pain Baseline Intervention 74 52–96
Control 84 62–100 0.309
Outcome Intervention 84 62–100
Control 84 62–100 1.000
General health Baseline Intervention 77 63.25–97
Control 77 67–87 0.772
Outcome Intervention 82 67–92
Control 77 60–87 0.589
Abbreviations: IQR¼interquartile range; SF-36¼Short Form-36.
Table 6 Baseline and outcome hospital anxiety and depression scale
scores
P-value
Baseline Intervention Anxious 11
Not anxious 39
Control Anxious 21
Not anxious 60 0.611
Intervention Depressed 4
Not depressed 46
Control Depressed 9
Not depressed 72 0.563
Outcome Intervention Anxious 9
Not anxious 39
Control Anxious 13
Not anxious 61 0.868
Intervention Depressed 3
Not depressed 45
Control Depressed 5
Not depressed 69 0.912
Figures are number of people with a score of X8 defined as depressed or anxious.
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straditional hospital follow-up. In addition, it is clear that groups
of health professionals, including GPs and specialist nurses,
are willing, with certain caveats, to assume greater respon-
sibility for the routine follow-up of patients with cancer
(Grunfeld et al, 1995; Papagrigoriadis and Heyman, 2001; Moses
et al, 2004; Cox et al, 2006). Our results seem to strengthen
these findings, as they support the notion that GP-led follow-up
would be attractive to a large proportion of individuals with
melanoma, and their GPs. It is important to be aware, however,
that this is just one alternative model for the delivery of cancer
follow-up care.
Meaning and implications
Our results show that an integrated programme of routine GP-led
follow-up for patients with cutaneous melanoma is feasible, at least
in North-east Scotland. Receipt of follow-up in general practice,
instead of at the hospital outpatient clinic, did not significantly
increase anxiety or depression among participants, or impair their
health status, although, as these were secondary outcomes, we had
limited power to state this definitively. These, although limited,
data are consistent with earlier work suggesting that most
recurrent cancers are detected in the interval between routine
follow-up appointments. Overall, the data support an emerging
literature which suggests that GP-led follow-up confers important
benefits in patient satisfaction, without adverse effects on the
psychological and physical well-being of patients, at least in the
short term. This finding needs to be confirmed in large-scale
randomised trials powered on hard clinical outcomes, such as
recurrence and mortality.
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